PT1748756E - Composições compreendendo drospirenona molecularmente dispersa - Google Patents

Composições compreendendo drospirenona molecularmente dispersa Download PDF

Info

Publication number
PT1748756E
PT1748756E PT05708751T PT05708751T PT1748756E PT 1748756 E PT1748756 E PT 1748756E PT 05708751 T PT05708751 T PT 05708751T PT 05708751 T PT05708751 T PT 05708751T PT 1748756 E PT1748756 E PT 1748756E
Authority
PT
Portugal
Prior art keywords
compositions
molecularly dispersed
drospirenone
drospirenone molecularly
gastro
Prior art date
Application number
PT05708751T
Other languages
English (en)
Inventor
Torsten Wagner
Adrian Funke
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34961545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1748756(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PT1748756E publication Critical patent/PT1748756E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
PT05708751T 2004-03-10 2005-03-10 Composições compreendendo drospirenona molecularmente dispersa PT1748756E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55135504P 2004-03-10 2004-03-10
EP04075713 2004-03-10

Publications (1)

Publication Number Publication Date
PT1748756E true PT1748756E (pt) 2009-07-20

Family

ID=34961545

Family Applications (1)

Application Number Title Priority Date Filing Date
PT05708751T PT1748756E (pt) 2004-03-10 2005-03-10 Composições compreendendo drospirenona molecularmente dispersa

Country Status (22)

Country Link
EP (2) EP1748756B1 (pt)
JP (2) JP2007528388A (pt)
KR (1) KR20060130723A (pt)
AT (2) ATE429900T1 (pt)
AU (2) AU2005221402B2 (pt)
BR (1) BRPI0508612A (pt)
CA (1) CA2558393A1 (pt)
CR (1) CR8631A (pt)
CU (1) CU20060173A7 (pt)
CY (1) CY1109265T1 (pt)
DE (1) DE602005014227D1 (pt)
DK (1) DK1748756T3 (pt)
EA (1) EA012570B1 (pt)
EC (1) ECSP066901A (pt)
ES (1) ES2325591T3 (pt)
HR (1) HRP20090381T1 (pt)
IL (1) IL177893A0 (pt)
NZ (1) NZ549792A (pt)
PL (1) PL1748756T3 (pt)
PT (1) PT1748756E (pt)
SI (1) SI1748756T1 (pt)
WO (1) WO2005087194A1 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
US8475838B2 (en) 2005-06-03 2013-07-02 Sandoz Ag Rapidly-dissolving pharmaceutical composition for inhibiting ovulation
EP1767194A1 (de) * 2005-06-09 2007-03-28 Helm AG Verfahren zur Herstellung von Adsorbaten des Drospirenons
US20070104780A1 (en) * 2005-10-25 2007-05-10 Lipari John M Formulation comprising a drug of low water solubility and method of use thereof
WO2009138224A1 (en) * 2008-05-14 2009-11-19 Helm Ag Pharmaceutical composition comprising drospirenone
EP3210474B1 (en) * 2008-09-17 2020-11-18 Chiasma, Inc. Pharmaceutical compositions comprising polypeptides and related methods of delivery
US8512745B2 (en) 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
EP2398461A1 (en) * 2009-02-18 2011-12-28 Bayer Pharma Aktiengesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
ES2742525T3 (es) 2009-10-01 2020-02-14 Adare Pharmaceuticals Us L P Composiciones de corticosteroides administradas oralmente
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
EP3459533A1 (en) 2010-08-04 2019-03-27 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN103040725B (zh) * 2012-12-26 2015-01-21 武汉九珑人福药业有限责任公司 一种利用研磨改善屈螺酮溶出的方法及屈螺酮固体分散体
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
MY176771A (en) 2013-06-25 2020-08-21 Olam International Ltd Processes for producing dark brown natural cocoa
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
RU2016141135A (ru) 2014-07-29 2018-08-28 Терапьютиксмд, Инк. Трансдермальный крем
MA41462A (fr) 2015-02-03 2021-05-12 Chiasma Inc Méthode de traitement de maladies
US10596118B2 (en) * 2015-03-10 2020-03-24 Shionogi, Inc. Solid dispersions
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5770815A (en) * 1980-10-21 1982-05-01 Furointo Sangyo Kk Absorption improver
JPS5942313A (ja) * 1982-09-01 1984-03-08 Teijin Ltd ポリビニルポリピロリドンを用いた製剤
JPH0723303B2 (ja) * 1986-03-07 1995-03-15 株式会社資生堂 難溶性薬物含有マイクロエマルシヨン製剤
DE3702029A1 (de) * 1987-01-24 1988-08-04 Basf Ag Waessriges oder pulverfoermiges, wasserdispergierbares praeparat eines in wasser schwerloeslichen pharmazeutischen wirkstoffs und verfahren zu seiner herstellung
DE3916112A1 (de) * 1989-05-16 1990-11-22 Schering Ag Dihydrospirorenon als antiandrogen
DE4326240A1 (de) 1993-08-02 1995-02-09 Schering Ag 15,15-Dialkyl-substituierte Derivate des Estradiols
JPH11514979A (ja) * 1995-09-07 1999-12-21 フイズ テクノロジーズ リミテッド 実質的に非溶解性の生体作用薬剤をバイオ・アベイラブルにするシステム
US5789442A (en) 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
JP2002513750A (ja) * 1998-05-07 2002-05-14 エラン コーポレーシヨン ピーエルシー 溶媒／助溶剤を含まないマイクロエマルジョン及びエマルジョンプレ濃縮物のドラッグデリバリーシステム
ME00329B (me) * 1999-08-31 2011-05-10 Bayer Schering Pharma Ag Farmaceutska kombinacija etiilestradiola i drospirenona za primjenu kao kontraceptiynog sredstva
SI1611892T1 (sl) * 2000-01-18 2010-01-29 Bayer Schering Pharma Ag Farmacevtski sestavki, ki obsegajo drospirenon
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
ATE452641T1 (de) 2002-09-05 2010-01-15 Pantarhei Bioscience Bv Orale pharmazeutische zusammensetzung enthaltend 15-hydroxytestosteron und seine derivate
DK1558265T3 (da) * 2002-11-05 2010-03-15 Bayer Schering Pharma Ag Anvendelse af dropspirenon til behandling af hypertension

Also Published As

Publication number Publication date
IL177893A0 (en) 2006-12-31
NZ549792A (en) 2009-12-24
PL1748756T3 (pl) 2009-10-30
EP1980242B1 (en) 2010-08-11
EA200601570A1 (ru) 2007-02-27
AU2005221402B2 (en) 2009-12-17
ECSP066901A (es) 2006-12-20
CY1109265T1 (el) 2014-07-02
DK1748756T3 (da) 2009-06-15
EP1980242A1 (en) 2008-10-15
DE602005014227D1 (de) 2009-06-10
CR8631A (es) 2007-06-06
ATE429900T1 (de) 2009-05-15
EP1748756B1 (en) 2009-04-29
CA2558393A1 (en) 2005-09-22
AU2009240844A1 (en) 2009-12-17
EP1748756A1 (en) 2007-02-07
SI1748756T1 (sl) 2009-10-31
KR20060130723A (ko) 2006-12-19
WO2005087194A1 (en) 2005-09-22
ATE476961T1 (de) 2010-08-15
AU2005221402A1 (en) 2005-09-22
JP2010150289A (ja) 2010-07-08
HRP20090381T1 (en) 2009-09-30
ES2325591T3 (es) 2009-09-09
EA012570B1 (ru) 2009-10-30
CU20060173A7 (es) 2009-09-08
JP2007528388A (ja) 2007-10-11
BRPI0508612A (pt) 2007-08-14

Similar Documents

Publication Publication Date Title
IL177893A0 (en) Compositions comprising drospirenone molecularly dispersed
WO2006113505A3 (en) Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
WO2008021368A3 (en) Compositions and methods for neuroprotection
WO2007149406A3 (en) Modified coagulation factor ix polypeptides and use thereof for treatment
WO2006002365A3 (en) Microparticles with high loadings of a bioactive agent
WO2007008752A3 (en) Sustained release pharmaceutical compositions for highly water soluble drugs
IL184758A0 (en) New pharmaceutical compositions useful in the transmucosal administration of drugs
HUP0500509A3 (en) Micronized pharmaceutical or nutraceutical powder with immediate release
WO2004093795A3 (en) Compositions for delivery of drug combinations
WO2008033351A3 (en) Multimodal abuse resistant and extended release formulations
IL196426A (en) Micro-particles based on amphiphilic copolymer, their preparation processes and their pharmaceutical preparations
DE60216305D1 (de) Zusammensetzungen zur verabreichung von arzneimittelkombinationen
WO2007017331A3 (en) Immediate release therapeutic systems for improved oral absorption of 7- [ (e) -tert-butyloxyiminomethyl] camptothecin
IL189270A (en) Repamycins converted to phosphonate and their derivatives, pharmaceutical preparations containing them and their use in the prevention and treatment of bone and joint infections
PT1742927E (pt) Derivados do ácido butanóico, processos para a sua preparação, composições farmacêuticas que os contêm, e suas aplicações terapêuticas
ZA200804207B (en) Pharmaceutical composition comprising at least one anticancer drug and at least one polymer
HK1120417A1 (en) Stable nanoparticle formulations
WO2009048940A3 (en) Diacerein pharmaceutical formulations
WO2006128120A3 (en) Novel lapachone compounds and methods of use thereof
TW200609000A (en) Molecular dispersions of drospirenone
WO2004096125A3 (en) Pharmaceutical compositions releasing their active agents from a buccal or sublingual location to overcome an absorption window problem
WO2007135293A3 (fr) 2-alcoxy-3,4,5-trihydroxy-alkylamide-benzazepine, leur préparation, compositions les contenant et utilisation
ZA200706710B (en) 6-Phenylhex-5-enoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions them, and therapeutic uses thereof
WO2007135294A3 (fr) 2-alcoxy-3,4,5-trihydroxy-alkylamide-benzothiazepine, leur préparation, compositions les contenant et utilisation
TH93875B (th) สารผสมตามสูตรที่ออกฤทธิ์ช้า ซึ่งประกอบด้วยออกทรีโอไทด์และพอลิแลคไทด์-โค-ไกลโคไลด์ พอลิเมอร์สองตัวหรือมากกว่า